New hope for tough-to-treat myeloma: trial combines smart drugs to beat cancer

NCT ID NCT07053436

Recruiting now Disease control Sponsor: Multiple Myeloma Research Consortium Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is for people newly diagnosed with a high-risk form of multiple myeloma, a blood cancer. It tests several new drug combinations to see which works best at killing cancer cells and keeping the disease from coming back. About 300 participants will receive different treatments, and the study will track how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA

Contacts and locations

Locations

Emory University
RECRUITING

Atlanta, Georgia, 30017, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55902, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
UChicago Medicine
RECRUITING

Chicago, Illinois, 60637, United States
UNC
RECRUITING

Chapel Hill, North Carolina, 27599, United States
Washington University Medical Center
RECRUITING

St Louis, Missouri, 63130, United States